Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 76 articles: HTML format

Single Articles

April 2024
1. MURPHY S, Rahmy S, Gan D, Liu G, et al
   Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
   Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
   PubMed     Abstract available
   
   
   March 2024
2. SHU F, Liu H, Chen X, Liu Y, et al
   m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
   Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
   PubMed     Abstract available
   
   
   January 2024
3. ZHAO J, Xu N, Zhu S, Nie L, et al
   Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
   Cancer Res. 2024;84:154-167.
   PubMed     Abstract available
   
   
   December 2023
4. MISHRA R, Blinka S, Hsieh AC
   Citron Kinase Is a Druggable Target in Treatment-Resistant Prostate Cancer.
   Cancer Res. 2023;83:4008-4009.
   PubMed     Abstract available
   
   
   
5. AWAD D, Cao PHA, Pulliam TL, Spradlin M, et al
   Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
   Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-0555.
   PubMed     Abstract available
   
   
   October 2023
6. RAWAT C, Ben-Salem S, Singh N, Chauhan G, et al
   Prostate cancer progression relies on the mitotic kinase citron kinase.
   Cancer Res. 2023 Oct 6. doi: 10.1158/0008-5472.CAN-23-0883.
   PubMed     Abstract available
   
   
   September 2023
7. LI Z, Ning K, Zhao D, Zhou Z, et al
   Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling.
   Cancer Res. 2023 Sep 7. doi: 10.1158/0008-5472.CAN-23-0308.
   PubMed     Abstract available
   
   
   
8. BORDELEAU F
   Using Machine Learning to Predict TP53 Mutation Status and Aggressiveness of Prostate Cancer from Routine Histology Images.
   Cancer Res. 2023;83:2809-2810.
   PubMed     Abstract available
   
   
   
9. NYQUIST MD, Coleman IM, Lucas JM, Li D, et al
   Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
   Cancer Res. 2023;83:2938-2951.
   PubMed     Abstract available
   
   
   August 2023
10. GALLAHER J, Strobl M, West J, Gatenby R, et al
    Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.
    Cancer Res. 2023;83:2775-2789.
    PubMed     Abstract available
    
    
    
11. SUN R, Yan B, Li H, Ding D, et al
    Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis.
    Cancer Res. 2023 Aug 1:CAN-23-0285. doi: 10.1158/0008-5472.CAN-23-0285.
    PubMed     Abstract available
    
    
    July 2023
12. LI X, Mu P
    The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
    Cancer Res. 2023 Jul 28:CAN-23-2260. doi: 10.1158/0008-5472.CAN-23-2260.
    PubMed     Abstract available
    
    
    June 2023
13. PIZURICA M, Larmuseau M, Van der Eecken K, de Schaetzen van Brienen L, et al
    Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer.
    Cancer Res. 2023 Jun 23:CAN-22-3113. doi: 10.1158/0008-5472.CAN-22-3113.
    PubMed     Abstract available
    
    
    
14. LUNDBERG A, Zhang M, Aggarwal R, Li H, et al
    The genomic and epigenomic landscape of double-negative metastatic prostate cancer.
    Cancer Res. 2023 Jun 8:CAN-23-0593. doi: 10.1158/0008-5472.CAN-23-0593.
    PubMed     Abstract available
    
    
    April 2023
15. FLOC'H N, Kinkade CW, Kobayashi T, Aytes A, et al
    Editor's Note: Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model.
    Cancer Res. 2023;83:1160.
    PubMed    
    
    
    
16. OUYANG X, Jessen WJ, Al-Ahmadie H, Serio AM, et al
    Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer.
    Cancer Res. 2023;83:1161.
    PubMed    
    
    
    
17. WANG K, Ma F, Arai S, Wang Y, et al
    WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.
    Cancer Res. 2023;83:1016-1030.
    PubMed     Abstract available
    
    
    March 2023
18. ZHANG X, Cheng L, Gao C, Chen J, et al
    Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-kappaB Activation in T Cells and Suppressing Antitumor Immunity.
    Cancer Res. 2023;83:906-921.
    PubMed     Abstract available
    
    
    
19. LI M, Liu M, Han W, Wang Z, et al
    LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer.
    Cancer Res. 2023 Mar 6:CAN-22-2433. doi: 10.1158/0008-5472.CAN-22-2433.
    PubMed     Abstract available
    
    
    February 2023
20. AO J, Shao X, Liu Z, Liu Q, et al
    Stimulated Raman Scattering Microscopy Enables Gleason Scoring of Prostate Core Needle Biopsy by a Convolutional Neural Network.
    Cancer Res. 2023;83:641-651.
    PubMed     Abstract available
    
    
    
21. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    PubMed     Abstract available
    
    
    
22. BLATTI C, de la Fuente Cedeno J, Gao H, Marin-Goni I, et al
    Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer.
    Cancer Res. 2023 Feb 13:CAN-22-1910. doi: 10.1158/0008-5472.CAN-22-1910.
    PubMed     Abstract available
    
    
    
23. GALLON J, Rodriguez-Calero A, Benjak A, Akhoundova D, et al
    DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations.
    Cancer Res. 2023 Feb 7:CAN-22-2236. doi: 10.1158/0008-5472.CAN-22-2236.
    PubMed     Abstract available
    
    
    January 2023
24. PATTERSON JC, Varkaris A, Croucher PJP, Ridinger M, et al
    Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
    Cancer Res. 2023;83:219-238.
    PubMed     Abstract available
    
    
    November 2022
25. CHOU J, Egusa EA, Wang S, Badura ML, et al
    Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer.
    Cancer Res. 2022 Nov 9. pii: 710533. doi: 10.1158/0008-5472.CAN-22-1433.
    PubMed     Abstract available
    
    
    
26. WU A, Attard G
    Accidentals of the DNA Symphony.
    Cancer Res. 2022;82:3880-3881.
    PubMed     Abstract available
    
    
    October 2022
27. SJOSTROM M, Zhao SG, Levy S, Zhang M, et al
    The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
    Cancer Res. 2022 Oct 17:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-1123.
    PubMed     Abstract available
    
    
    September 2022
28. WANG J, Ying G, Wang J, Jung Y, et al
    Retraction: Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression.
    Cancer Res. 2022;82:3405.
    PubMed    
    
    
    
29. WANG J, Lu Y, Wang J, Koch AE, et al
    Retraction: CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway.
    Cancer Res. 2022;82:3406.
    PubMed    
    
    
    
30. BHOWMICK S, Bhowmick NA
    RARgamma: The Bone of Contention for Endothelial Cells in Prostate Cancer Metastasis.
    Cancer Res. 2022;82:2975-2976.
    PubMed     Abstract available
    
    
    
31. LI H, Wang Y, Lin K, Venkadakrishnan VB, et al
    CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.
    Cancer Res. 2022;82:3088-3101.
    PubMed     Abstract available
    
    
    July 2022
32. YU G, Corn PG, Shen PF, Song JH, et al
    Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition.
    Cancer Res. 2022 Jul 8. pii: 706930. doi: 10.1158/0008-5472.CAN-22-0170.
    PubMed     Abstract available
    
    
    
33. DAVIDSON SM, Schmidt DR, Heyman JE, O'Brien JP, et al
    Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.
    Cancer Res. 2022;82:2403-2416.
    PubMed     Abstract available
    
    
    June 2022
34. SHANGGUAN X, Ma Z, Yu M, Ding J, et al
    Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer.
    Cancer Res. 2022 Jun 29. pii: 705311. doi: 10.1158/0008-5472.CAN-21-3822.
    PubMed     Abstract available
    
    
    
35. BERCHUCK JE, Adib E, Abou Alaiwi S, Dash AK, et al
    The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response.
    Cancer Res. 2022 Jun 22. pii: 705059. doi: 10.1158/0008-5472.CAN-21-3552.
    PubMed     Abstract available
    
    
    
36. PATEL R, Ford CA, Rodgers L, Rushworth LK, et al
    Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression.
    Cancer Res. 2022 Jun 8. pii: 704813. doi: 10.1158/0008-5472.CAN-21-1301.
    PubMed     Abstract available
    
    
    May 2022
37. QIN L, Chung YM, Berk M, Naelitz B, et al
    Hypoxia-reoxygenation couples 3betaHSD1 enzyme and cofactor upregulation to facilitate androgen biosynthesis and hormone therapy resistance in prostate cancer.
    Cancer Res. 2022 May 10. pii: 696493. doi: 10.1158/0008-5472.CAN-21-4256.
    PubMed     Abstract available
    
    
    
38. ABATE-SHEN C, Nunes de Almeida F
    Establishment of the LNCaP Cell Line - The Dawn of an Era for Prostate Cancer Research.
    Cancer Res. 2022;82:1689-1691.
    PubMed     Abstract available
    
    
    April 2022
39. RODRIGUEZ Y, Unno K, Truica MI, Chalmers ZR, et al
    A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer.
    Cancer Res. 2022 Apr 11. pii: 694256. doi: 10.1158/0008-5472.CAN-21-3565.
    PubMed     Abstract available
    
    
    March 2022
40. LI R, Zhu J, Zhong W, Jia Z, et al
    Comprehensive evaluation of machine learning models and gene expression signatures for prostate cancer prognosis using large population cohorts.
    Cancer Res. 2022 Mar 31. pii: 682141. doi: 10.1158/0008-5472.CAN-21-3074.
    PubMed     Abstract available
    
    
    
41. KARABACAK NM, Zheng Y, Dubash TD, Burr R, et al
    Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.
    Cancer Res. 2022;82:1084-1097.
    PubMed     Abstract available
    
    
    February 2022
42. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    PubMed     Abstract available
    
    
    
43. IPPOLITO L, Comito G, Parri M, Iozzo M, et al
    Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer.
    Cancer Res. 2022 Feb 8. pii: 0008-5472.CAN-21-0914.
    PubMed     Abstract available
    
    
    
44. MA F, Arai S, Wang K, Calagua C, et al
    Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1807.
    PubMed     Abstract available
    
    
    January 2022
45. MANDIGO AC, Shafi AA, McCann JJ, Yuan W, et al
    Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.
    Cancer Res. 2022;82:221-234.
    PubMed     Abstract available
    
    
    December 2021
46. JIANG X, Guo S, Wang S, Zhang Y, et al
    EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling.
    Cancer Res. 2021 Dec 28. pii: 0008-5472.CAN-21-2988.
    PubMed     Abstract available
    
    
    
47. XIE W, Reder NP, Koyuncu CF, Leo P, et al
    Prostate cancer risk stratification via non-destructive 3D pathology with deep learning-assisted gland analysis.
    Cancer Res. 2021 Dec 1. pii: 0008-5472.CAN-21-2843.
    PubMed     Abstract available
    
    
    
48. HAWLEY JR, Zhou S, Arlidge C, Grillo G, et al
    Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.
    Cancer Res. 2021;81:5833-5848.
    PubMed     Abstract available
    
    
    November 2021
49. JUNG Y, Cackowski FC, Yumoto K, Decker AM, et al
    Correction: CXCL12gamma Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2021;81:5777.
    PubMed    
    
    
    
50. GIL V, Miranda S, Riisnaes R, Gurel B, et al
    HER3 is an Actionable Target in Advanced Prostate Cancer.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-3360.
    PubMed     Abstract available
    
    
    
51. GHILDIYAL R, Sawant M, Renganathan A, Mahajan K, et al
    Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance.
    Cancer Res. 2021 Nov 5. pii: 0008-5472.CAN-20-3845.
    PubMed     Abstract available
    
    
    
52. AL-JANABI H, Lewis CE
    Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer.
    Cancer Res. 2021;81:5399-5400.
    PubMed     Abstract available
    
    
    October 2021
53. KUMAR R, Mendonca J, Owoyemi O, Boyapati K, et al
    Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-20-3607.
    PubMed     Abstract available
    
    
    August 2021
54. BUTLER LM, Mah CY, Machiels J, Vincent AD, et al
    Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
    Cancer Res. 2021 Aug 6. pii: 0008-5472.CAN-20-3863.
    PubMed     Abstract available
    
    
    July 2021
55. LABRECQUE MP, Brown LG, Coleman IM, Lakely B, et al
    RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer.
    Cancer Res. 2021 Jul 26. pii: 0008-5472.CAN-21-0307.
    PubMed     Abstract available
    
    
    
56. EL-KENAWI A, Dominguez-Viqueira W, Liu M, Awasthi S, et al
    Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-4028.
    PubMed     Abstract available
    
    
    
57. MAVURA MY, Huang FW
    How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.
    Cancer Res. 2021;81:3764-3765.
    PubMed     Abstract available
    
    
    
58. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    PubMed     Abstract available
    
    
    
59. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available
    
    
    June 2021
60. PALLMANN N, Deng K, Livgard M, Tesikova M, et al
    Stress mediated reprogramming of prostate cancer one-carbon cycle drives disease progression.
    Cancer Res. 2021 Jun 28. pii: 0008-5472.CAN-20-3956.
    PubMed     Abstract available
    
    
    
61. WEI J, Yin L, Li J, Wang J, et al
    Bidirectional Crosstalk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
    Cancer Res. 2021 Jun 24. pii: 0008-5472.CAN-21-0198.
    PubMed     Abstract available
    
    
    
62. HUANG Z, Tang B, Yang Y, Yang Z, et al
    MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.
    Cancer Res. 2021 Jun 22. pii: 0008-5472.CAN-20-4194.
    PubMed     Abstract available
    
    
    
63. ENRIQUEZ C, Cancila V, Ferri R, Sulsenti R, et al
    Castration-induced down-regulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer.
    Cancer Res. 2021 Jun 21. pii: 0008-5472.CAN-21-0163.
    PubMed     Abstract available
    
    
    
64. SENA LA, Denmeade SR
    Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon?
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-21-1392.
    PubMed     Abstract available
    
    
    May 2021
65. OSMULSKI PA, Cunsolo A, Chen M, Qian Y, et al
    Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-3595.
    PubMed     Abstract available
    
    
    
66. MATSUSHITA M, Fujita K, Hayashi T, Kayama H, et al
    Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling.
    Cancer Res. 2021 May 26. pii: 0008-5472.CAN-20-4090.
    PubMed     Abstract available
    
    
    
67. MARTINEZ RS, Salji MJ, Rushworth L, Ntala C, et al
    SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-3694.
    PubMed     Abstract available
    
    
    
68. RAHMAN NIA, Sato A, Tsevelnorov K, Shimizu A, et al
    Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.
    Cancer Res. 2021;81:2318-2331.
    PubMed     Abstract available
    
    
    
69. LIU Z, Guo C, Das SK, Yu X, et al
    Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
    Cancer Res. 2021;81:2429-2441.
    PubMed     Abstract available
    
    
    April 2021
70. MATTHIAS J, Engelhardt J, Schafer M, Bauder-Wust U, et al
    Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Cancer Res. 2021;81:2234-2245.
    PubMed     Abstract available
    
    
    
71. LACHANCE J
    Beyond Stamp Collecting: Evolutionary and Functional Genomics Advance Our Understanding of Cancer Biology.
    Cancer Res. 2021;81:1637-1638.
    PubMed     Abstract available
    
    
    March 2021
72. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed     Abstract available
    
    
    February 2021
73. PASCHALIS A, Welti J, Neeb AJ, Yuan W, et al
    JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
    Cancer Res. 2021;81:1087-1100.
    PubMed     Abstract available
    
    
    
74. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed     Abstract available
    
    
    January 2021
75. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available
    
    
    
76. SOLEIMANY AP, Kirkpatrick JD, Su S, Dudani JS, et al
    Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer.
    Cancer Res. 2021;81:213-224.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.